Pathologically, HL tumor cells share aberrant survival by activation of NFkB-signalling while downregulation of several master factors controlling B-cell differentiation, including PAX5 and EBF1 is restricted to classical HL [23–25]. The gene discussed is PAX5; the disease is Hodgkins lymphoma.